A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin

Mary F. Mulcahy*, Patrick J. Loehrer, Neal J. Meropol, Alfred W. Rademaker, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Cisplatin, 5-fluorouracil (5-FU) and docetaxel are active agents in the treatment of upper gastrointestinal malignancies. This phase I study was undertaken to determine the maximally tolerated dose and dose-limiting toxicities of a combination of these drugs given in an ambulatory setting using a bolus schedule of 5-FU. Methods: Twenty patients with gastrointestinal malignancies were treated with docetaxel on day 1, cisplatin on day 2 and bolus 5-FU with leucovorin each day for 5 days, without prophylactic antibiotics or colony-stimulating factors. The cycle was repeated at 21-day intervals. A dose-escalating phase I design was used. Results: There were two treatment-related deaths as a result of neutropenia and sepsis. The maximally tolerated dose was docetaxel at 60 mg/m2 on day 1, cisplatin at 75 mg/m2 on day 2 and 5-FU at 200 mg/m2 with leucovorin at 20 mg/m2 daily from day 1 to day 5. At this dose, neutropenia was occurring in 4 of 6 patients treated. There were three partial responses, 1 patient with esophagogastric cancer and 2 with gastric cancer. Conclusions: This regimen demonstrates efficacy in upper gastrointestinal malignancies. Strategies to improve the tolerance of these agents in combination should be pursued.

Original languageEnglish (US)
Pages (from-to)479-484
Number of pages6
JournalONCOLOGY
Volume68
Issue number4-6
DOIs
StatePublished - Aug 1 2005

Keywords

  • Docetaxel
  • Gastric cancer
  • Phase I trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin'. Together they form a unique fingerprint.

Cite this